A Phase 4 interventional study of Atock Dry Syrup with placebo patch and Tulobuterol patch with placebo dry syrup in Acute Bronchitis, sponsored by SamA Pharmaceutical Co., Ltd. Recruiting at 1 site in South Korea. Open to participants aged 6 Months to 11 Years. Per ClinicalTrials.gov, last updated 2025-09-23.
Sponsored by SamA Pharmaceutical Co., Ltd · Phase 4, Interventional, and Treatment
Clinical Study to Evaluate the Efficacy and Safety of Atock Dry Syrup with Acute bronchial Patients
156 studies on the registry are indexed under Bronchitis; 21 are open to participants now.
This study's planned enrollment of 296 is above the median of 185 across 105 interventional studies indexed under Bronchitis.
Browse Bronchitis studies →SamA Pharmaceutical Co., Ltd is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Atock Dry Syrup with placebo patch
Drug: Tulobuterol patch with placebo dry syrup
Atock Dry syrup (TID) with placebo patch (QD)
Tulobuterol patch (QD) with placebo dry syrup (TID)
The rate of subjects whose symptoms improved based on the wheezing score at 3 days
The rating was: 0=No wheezing (None); 1=mild (End expiration with stethoscope); 2=moderate (Inspiration and expiration with stethoscope) and 3=severe (Audible without stethoscope).
Time frame: 3 days treatment period
The rate of subjects whose symptoms improved based on the wheezing score at 7 days
Time frame: 7 days treatment period
The rate of subjects whose wheezing score improved by two or more grades at 3 and 7 days
Time frame: 3 and 7 days treatment period
The change in bronchitis severity score excluding the sputum (BSSEs) at 3 and 7 days
• The BSSEs comprises the following four symptoms typical for Acute Bronchitis: cough, chest pain on coughing, crackle and dyspnea. These symptoms are each assessed according to a 5-point Likert scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe and 4 = very severe
Time frame: 3 and 7 days treatment period
The change in patient satisfaction scores for wheezing (VAS, Visual Analogue Scale) at 3 and 7 days
VAS consists of a horizontal line, usually 100 in length and select a point on the scale indicating the level of satisfaction for wheezing in the 3 and 7 days. The number 0 indicates not satisfaction and 100 indicates very satisfaction.
Time frame: 3 and 7 days treatment period
The change in patient satisfaction scores for cough (COAT, COugh Assessment Test) at 3 and 7 days
All items can be scored as a single scale (0-4 scaling of each item, 0-20 total score range). Higher scores represent more severe cough.
Time frame: 3 and 7 days treatment period
Started Nov 2023 (actual). Primary completion is estimated for Jul 2027, 44 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SamA Pharmaceutical Co., Ltd